How cellular metabolic state impacts cellular programs is a fundamental, unresolved question. Here we investigated how glycolytic flux impacts embryonic development, using pre-somitic mesoderm (PSM) patterning as the experimental model. First, we identified fructose 1,6-bisphosphate (FBP) as an in vivo sentinel metabolite that mirrors glycolytic flux within PSM cells of post-implantation mouse embryos. We found that medium-supplementation with FBP, but not with other glycolytic metabolites, such as fructose 6-phosphate and 3-phosphoglycerate, impaired mesoderm segmentation. To genetically manipulate glycolytic flux and FBP levels, we generated mouse models enabling the conditional overexpression of dominant active, cytoplasmic Pfkfb3 (cytoPfkfb3). Overexpression of cytoPfkfb3 indeed led to increased glycolytic flux/FBP levels and caused an impairment of mesoderm segmentation, paralleled by the downregulation of Wnt-signaling, reminiscent of the effects seen upon FBP-supplementation. To probe for mechanisms underlying glycolytic flux-signaling, we performed sub-cellular proteome analysis and revealed that cytoPfkfb3 overexpression altered subcellular localization of certain proteins, including glycolytic enzymes, in PSM cells. Specifically, we revealed that FBP supplementation caused depletion of Pfkl and Aldoa from the nuclear-soluble fraction. Combined, we propose that FBP functions as a flux-signaling metabolite connecting glycolysis and PSM patterning, potentially through modulating subcellular protein localization.

Importantly, the role of metabolite signaling is not limited to detecting nutrient availability to match metabolic activity and cellular demands. Recent work has highlighted the emerging link between central carbon metabolism and other cellular programs, such as gene regulation. For instance, by controlling the abundance of rate-limiting substrates used for post-translational modifications, such as acetyl-CoA, metabolic activity can directly impact gene expression (7–9). Glycolytic metabolites can also serve as signaling molecules that impact signal transduction directly. In yeast, for example, the glycolytic metabolite fructose 1,6-bisphosphate (FBP) has been shown to regulate the pro-proliferative RAS signaling cascade by interacting with the guanine nucleotide exchange factor Sos1 (10). Notably, the connection between metabolic activity and other cellular programs can also occur at the level of metabolic enzymes with non-canonical, moonlighting functions (9, 11, 12). In situations when moonlighting and canonical enzyme function are inter-dependent, a direct link between cellular metabolic state and moonlighting function is established. One such example is the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (Gapdh), which moonlights as an RNA-binding protein regulating translation when not engaged in its glycolytic function (13). While these studies highlight an intricate link between central carbon metabolism and other cellular functions, knowledge of metabolite signaling in more complex physiological settings, such as embryonic development, is still limited.

There are both classic (14) as well as more recent findings (9, 15–21) indicating that glucose metabolism and developmental programs are indeed linked. For instance, in mouse and chick embryos, the presomitic mesoderm (PSM) shows intrinsic differences in the expression levels of glycolytic enzymes, leading to the establishment of a glycolytic
activity gradient along the anterior-posterior axis (15, 16). The key question that remains largely unanswered is how a change in cellular metabolic activity is sensed and mechanistically linked to developmental programs. To address this fundamental question, we focused on mouse embryos at the organogenesis stage following gastrulation, when glucose metabolism is rewired dynamically in time and space in response to extrinsic environmental cues and intrinsic developmental programs (15–17). At this stage, the PSM is periodically segmented into somites, the precursors of vertebrae and skeletal muscles in vertebrates (22). PSM patterning and somite formation is controlled by the Wnt, FGF, and retinoic acid-signaling pathways, which show a graded activity along the anterior-posterior axis. In addition, PSM segmentation is linked to a molecular oscillator, the segmentation clock, comprised of several, interconnected signaling pathways (Notch, Wnt, Fgf) that show rhythmic activation.

Termination and somite formation is controlled by the Wnt, FGF, and BMP pathways that show a graded activity along the anterior-posterior axis. In addition, PSM segmentation is linked to a molecular oscillator, the segmentation clock, comprised of several, interconnected signaling pathways (Notch, Wnt, Fgf) that show rhythmic activation.

Alternative mesoderm development caused specifically by FBP supplementation.

To test for a potential functional role of those sentinel metabolites that we identified, we next performed medium-supplementing experiments with the goal of altering intracellular metabolic levels. To this end, we supplemented the control culture medium with high levels of either fructose 6-phosphate (F6P), FBP, or 3-phosphoglycerate (3PG) and scored the effect at the level of morphological segment formation, elongation, and also oscillatory segmentation clock activity, using real-time imaging quantifications. Interestingly, FBP supplementation impaired mesoderm segmentation and elongation and disrupted segmentation clock activity in the posterior PSM (Figure 2A, S2A, S2B). In contrast, glycolytic metabolites upstream (i.e., F6P) or downstream (i.e., 3PG, pyruvate) of FBP did not cause such effects (Figure 2A, S2A, S2B; the effect of pyruvate supplementation was described in (15)). We also tested the effect of FBP supplementation on gene expression, focusing on an FGF-target gene Dusp4 (31) and a Wnt-target gene Msgn (32). Supplementation of FBP, but not F6P, caused a downregulation of Dusp4 and Msgn mRNA expression in a dose-dependent manner (Figure 2B), accompanying reduction of mesoderm segmentation and elongation (Figure 2C, 2D). Of note, at intermediate concentration (10 mM) of FBP supplementation, only the Wnt-target gene Msgn was downregulated, while the Fgf-target gene Dusp4 showed expression comparable to control samples, indicating potential dose-specific effects of FBP.

To validate the effects seen upon exogenous addition of FBP, we investigated the uptake of FBP by stable isotope (13C) tracing. We cultured PSM explants in medium supplemented with fully 13C-labelled FBP (13C-FBP) and analyzed 13C-labelling of intracellular metabolites by liquid chromatography mass spectrometry (LC-MS). Following three hours of incubation with 13C-FBP, 13C-labeling was detected in glycolytic intermediates downstream of FBP (Figure S2C), confirming the uptake of labeled carbons by the explants. Since we also detected that a small fraction of 13C-FBP broke down to 13C-fructose monophosphate (F6P and/or fructose 1-phosphate (F1P)) in the culture medium during incubation (data not shown), we performed additional control experiments by culturing PSM explants in F1P-supplemented medium. Similar to F6P, supplementation of F1P did not cause any detectable phenotype at the level of segmentation clock activity or elongation (Figure S2D).

Results

Steady state levels of FBP mirror glycolytic flux within PSM cells.

In order to identify sentinel metabolites whose levels respond to a change in glycolytic flux within PSM cells, we quantified steady state metabolite levels in PSM samples cultured in a range of glucose concentrations (0.5 mM to 10 mM glucose). We first verified that higher glucose concentrations led to higher glycolytic activity in PSM cells using lactate secretion as a proxy (Figure 1A). Also, we analyzed somite formation and PSM patterning at different glucose concentrations (Figure S1). Using real-time imaging of the segmentation clock as a dynamic readout, we found ongoing periodic morphological segmentation, axis elongation, and oscillatory clock activity throughout the PSM. Segmentation proceeded normally, at least qualitatively, at these glucose concentrations. We then used this experimental setting to analyze steady state levels of metabolites in central carbon metabolism by gas chromatography mass spectrometry (GC-MS), following three-hour incubation of PSM explants at glucose concentrations ranging from 0.5 mM to 10 mM. Amongst the 57 metabolites quantified, 14 metabolites showed significant linear correlation (p-value < 0.01) with extracellular glucose levels (Figure 1B). In particular, fructose 1,6-bisphosphate (FBP) showed the highest positive linear relationship (Pearson correlation coefficient = 0.99) with extracellular glucose availability. Notably, unlike secreted lactate levels, the linear relationship was maintained across all glucose concentrations examined (Figure 1A). In addition, FBP showed the highest fold-change response to glucose titration with a 45-fold increase in its levels from 0.5 mM to 10 mM glucose (Figure 1A, 1C). These results show that steady state FBP levels tightly reflect glucose availability, indicating the potential of FBP to serve as a sentinel metabolite for glycolytic-flux within PSM cells.

To test for a potential functional role of those sentinel metabolites that we identified, we next performed medium-supplementing experiments with the goal of altering intracellular metabolic levels. To this end, we supplemented the control culture medium with high levels of either fructose 6-phosphate (F6P), FBP, or 3-phosphoglycerate (3PG) and scored the effect at the level of morphological segment formation, elongation, and also oscillatory segmentation clock activity, using real-time imaging quantifications. Interestingly, FBP supplementation impaired mesoderm segmentation and elongation and disrupted segmentation clock activity in the posterior PSM (Figure 2A, S2A, S2B). In contrast, glycolytic metabolites upstream (i.e., F6P) or downstream (i.e., 3PG, pyruvate) of FBP did not cause such effects (Figure 2A, S2A, S2B; the effect of pyruvate supplementation was described in (15)). We also tested the effect of FBP supplementation on gene expression, focusing on an FGF-target gene Dusp4 (31) and a Wnt-target gene Msgn (32). Supplementation of FBP, but not F6P, caused a downregulation of Dusp4 and Msgn mRNA expression in a dose-dependent manner (Figure 2B), accompanying reduction of mesoderm segmentation and elongation (Figure 2C, 2D). Of note, at intermediate concentration (10 mM) of FBP supplementation, only the Wnt-target gene Msgn was downregulated, while the Fgf-target gene Dusp4 showed expression comparable to control samples, indicating potential dose-specific effects of FBP.

To validate the effects seen upon exogenous addition of FBP, we investigated the uptake of FBP by stable isotope (13C) tracing. We cultured PSM explants in medium supplemented with fully 13C-labelled FBP (13C-FBP) and analyzed 13C-labelling of intracellular metabolites by liquid chromatography mass spectrometry (LC-MS). Following three hours of incubation with 13C-FBP, 13C-labeling was detected in glycolytic intermediates downstream of FBP (Figure S2C), confirming the uptake of labeled carbons by the explants. Since we also detected that a small fraction of 13C-FBP broke down to 13C-fructose monophosphate (F6P and/or fructose 1-phosphate (F1P)) in the culture medium during incubation (data not shown), we performed additional control experiments by culturing PSM explants in F1P-supplemented medium. Similar to F6P, supplementation of F1P did not cause any detectable phenotype at the level of segmentation clock activity or elongation (Figure S2D).
As a related finding, we observed that upon glucose titration, the expression of Wnt-signaling target genes in PSM explants is anti-correlated with glucose availability/glycolytic activity: while lowering glucose concentration (from 5.0 mM to 0.5 mM) correlated with an upregulation of several Wnt target genes, such as Axin2, Ccnd1, and Myc, the opposite effect was found when glucose concentration was increased (from 5.0 mM to 25 mM) (Figure S3).

Combined, our findings hence suggest that FBP, but not other glycolytic intermediates such as F6P, F1P or 3PG, is a flux-sentinel and signaling metabolite, as it impacts mesoderm development and gene expression in a dose-dependent manner.

Generating a conditional cytoPfkfb3 transgenic mouse line as a genetic tool to increase glycolysis. Our findings thus far show that intracellular FBP levels respond dynamically to an alteration in glycolytic flux (Figure 1), and importantly, that FBP, but not its precursor metabolite F6P, impacts PSM development in a dose-dependent manner (Figure 2). Based on these observations, we next sought a way to manipulate glycolytic flux at the level of the phosphofructokinase (Pfk) reaction and importantly, in a genetic manner (Figure 3A). Pfk converts F6P into FBP, the first committed step in glycolysis, and plays a critical role in regulating glycolytic flux (33, 34). We generated transgenic mice enabling conditional overexpression of a mutant Pfkfb3 [i.e. Pfkfb3(K472A/K473A) (35)]. Pfkfb3

![Fig. 1. Identifying sentinel metabolites that mirror glycolytic flux.](image-url)
Fig. 2. FBP supplementation impacts mesoderm segmentation and elongation in a dose-dependent manner. (A) Kymographs showing dynamics of the Notch signaling activity reporter LuVeLu in PSM explants treated with 20 mM of the indicated metabolite. (B) Whole mount in situ hybridization analysis for the FGF (i.e. Dusp4) and the Wnt target (i.e. Msgn) gene expression in the PSM. PSM explants were incubated for 12 hours in the presence of F6P or FBP. Expression domains of Dusp4 and Msgn are indicated by yellow squares. Shh and Uncx4.1 were used as a marker for the neural tissue and posterior somite boundary, respectively. Scale bar, 200 µm. (C, D) The number of newly formed somites (C) and the length of PSM explants (D) after 12-hour ex vivo culture (one-way ANOVA with Tukey’s post-hoc test, *p-value < 0.05, **p-value < 0.01, ***p-value < 0.001 versus control).
generates fructose 2,6-bisphosphate (F2,6BP), a potent allosteric activator of Pfk (Figure 3A). A previous study showed that Pkfb3(K472A/K473A) localises exclusively to the cytoplasm, and that this cytoplasmically-localized Pkfb3 (hereafter termed as cytoPkfb3) activates glycolysis (35). Indeed, in PSM explants from transgenic embryos with ubiquitous overexpression of cytoPkfb3, we found increased glycolysis based on the analysis of lactate secretion (Figure 3B). In addition, we found that in cytoPkfb3 embryos, lactate secretion changed in a glucose-dose dependent manner (Figure 3B). Next we investigated steady state metabolite levels in control and transgenic PSM explants cultured in 10 mM glucose condition. Among the 57 metabolites quantified by GC-MS, FBP and lactate were significantly increased in transgenic PSM explants, while aspartate, glucose 6-phosphate, and glutamate were significantly decreased (Figure 3C, S4). These findings mirrored the results in wild-type PSM explants upon glucose titration (Figure 1). We hence conclude, that the overexpression of cytoPkfb3 leads to activation of glycolysis at the level of Pfk. More generally, the cytoPkfb3 transgenic mouse line represents a potentially powerful new genetic model to study the role of glycolytic activation.

Functional consequence of cytoPkfb3 overexpression on PSM development.

We then investigated the functional consequences of cytoPkfb3 overexpression on mesoderm development. Constitutive overexpression of cytoPkfb3 from fertilization caused embryonic lethality, as no transgenic pups were recovered (n = 30 pups, N = 6 litters). We have not yet investigated the precise timepoint and cause of lethality. At embryonic day 10.5 (E10.5), cytoPkfb3 transgenic embryos were morphologically indistinguishable from their littermates, but had slightly fewer somites (Figure 4A; control: 38 ± 1.5 somites, transgenic: 35 ± 3.9 somites). To analyze the impact of cytoPkfb3 overexpression on mesoderm development in a more dynamic and quantitative manner, we analyzed mesoderm segmentation, elongation and oscillatory clock activity in cytoPkfb3 and control explants cultured at various glucose concentrations. Consistent with our previous findings (Figure S1), control explants proceeded with segmentation and PSM patterning in a qualitatively comparable manner, even when cultured at higher glucose concentrations (Figure 4B). We found that somite formation was impaired in explants from cytoPkfb3 embryos in a glucose-dose dependent manner (Figure 4B). Overall growth during this 12-hour incubation seemed comparable or even greater in cytoPkfb3 transgenic explants, based on the size of explants after culture (Figure 4C). We also tested whether a mesoderm-specific cytoPkfb3 overexpression has a similar effect on somite formation. Indeed, mesoderm specific cytoPkfb3 overexpression, using Cre-expression driven by the promoter of the pan-mesoderm marker Brachyury (i.e. T- promoter-driven Cre (36)), showed similar reduction in segment formation, compared to control explants (Figure 4E, 4F). The real-time imaging quantification of segmentation clock activity revealed that in cytoPkfb3 explants cultured at 10 mM glucose, clock oscillations ceased after few cycles, in contrast to control samples (Figure 4G).

Molecularly, we found that the expression of the Wnt signaling target gene Msnx was downregulated in cytoPkfb3 explants, again in a glucose-concentration dependent manner. In contrast, we did not find an obvious change in the expression of Dusp4, an Fgf signaling target, which was maintained even at 25 mM glucose (Figure 5A, 5B). Taken together, these results show that cytoPkfb3 overexpression, which we show leads to increased glycolytic flux, results in reduced segment formation, arrest of the segmentation clock oscillations and downregulation of Wnt-signaling target gene expression. In this regard, cytoPkfb3 overexpression mirrors the results obtained with exogenous FBP-supplementation.

cytoPkfb3 overexpression impairs neural tube closure ex vivo.

We also examined the effect of cytoPkfb3 overexpression on other developmental events, i.e. neural tube closure (NTC). NTC is known to be vulnerable to glucose metabolism perturbation associated with maternal diabetes (37). In order to address the impact of cytoPkfb3 overexpression on NTC, E8.5 cytoPkfb3 embryos were cultured for 24 hours at normoglycemic conditions (50% rat serum / DMEM with 1.0 g/L glucose), using the whole embryo roller-culture (WEC) system (38). While all control embryos completed cranial NTC (n = 12/12) after 24-hours WEC, about 40% of the transgenic embryos (n = 7/18) failed to complete this process (Figure S5A–S5C). We also noticed a tendency that cytoPkfb3 embryos with neural tube defects (NTDs) had fewer somites (18 ± 1.6 somites) compared to wild-type (22 ± 2.2 somites) or the transgenic embryos that completed NTC (20 ± 1.6 somites) (Figure S5B). These results indicate that cytoPkfb3 overexpression causes NTDs and a developmental delay when assessed in WEC. Interestingly, cytoPkfb3 transgenic embryos did not exhibit NTDs in vivo. We speculate this reflects a dependency of the NTD phenotype on environmental glucose concentrations, which are lower in vivo compared to WEC (39).

Perturbation of glycolytic-flux and FBP levels alters subcellular localization of glycolytic enzymes.

Our data thus far suggest that altered glycolysis, caused by either nutritional or genetic means, impairs PSM development, possibly mediated via the sentinel metabolite FBP. To probe for potential underlying mechanisms, we turned to the role of glycolytic enzymes. Interestingly, we had found that several glycolytic enzymes are localized in the nucleus in PSM cells, based on cell-fractionation analysis (Figure S6C, S6D). It had been proposed previously that the subcellular localization of glycolytic enzymes can change dynamically in response to altered glycolytic flux (40–42). We therefore aimed to systematically investigate the changes in subcellular protein localization in response to altered metabolic state in mouse embryos. To this end, we performed a proteome-wide cell-fractionation analysis in PSM explants cultured in various metabolic conditions.
Fig. 3. cytoPfkfb3 overexpression causes an increase in glycolytic flux and FBP levels within PSM cells. (A) Conditional cytoPfkfb3 transgenic mice were generated to activate glycolysis through allosteric activation of Pfk. (B) Quantification of secreted lactate in control and cytoPfkfb3 transgenic PSM explants cultured 12 hours under varying concentrations of glucose (unpaired Welch’s $t$-test, *$p$-value < 0.05, **$p$-value < 0.01). (C) Measurement of steady state metabolite levels by GC-MS (n = 4 biological replicates for each condition) in control (Ctrl) and cytoPFKfb3 (Tg; crossed to Hprt-Cre line) explants cultured for three hours in medium containing 10 mM glucose. SAM (Significance Analysis for Microarrays) analysis was performed using a significance threshold $\delta = 0.9$, which corresponds to a false discovery rate (FDR) = 0.012. G6P, glucose 6-phosphate. FBP, fructose 1,6-bisphosphate. 3PG, 3-phosphoglycerate. PEP, phosphoenolpyruvate. Asp, aspartate. Asn, asparagin.

Proteins were extracted from cytoplasmic, membrane, nuclear-soluble, chromatin-bound, and the remaining insoluble (labeled as 'cytoskeletal’) fractions. We found that in samples cultured three hours in FBP-supplemented medium (and to a lesser extend in F6P-supplemented medium), proteins part of the glycolytic pathway (12 combined glycolytic enzymes) were reduced in the cytoskeletal and, to a lesser extent, the nuclear soluble fraction, relative to samples cultured in control medium. (Figure 6A, S6A, S6B). For several glycolytic enzymes detected in the nuclear soluble fraction, i.e. aldolase A (Aldoa), phosphofructokinase L (PfkL), glyceraldehyde 3-phosphate dehydrogenase (Gapdh) and pyruvate kinase M (Pkm) (Figure S6E), we performed a targeted analysis using Western blotting. Interestingly, we found that amongst those tested enzymes, Aldoa and PfkL were significantly depleted from the nuclear soluble fraction upon incubation in FBP-supplemented medium (Figure 6B).

We next asked whether subcellular localization of glycolytic enzymes is also altered upon cytoPfkfb3 overexpression, which we showed leads to an increase in glycolytic flux and FBP levels (Figure 3B, 3C). We hence performed subcellular proteome analysis of both control and cytoPfkfb3 transgenic PSM explants, cultured for one hour in 10 mM glucose-containing medium. Due to the limited material obtained from transgenic embryos, proteins from nuclear-soluble, chromatin-bound, and cytoskeletal fractions were collected as a single, nuclear-cytoskeletal fraction. We found that cytoPfkfb3 overexpression altered the nuclear-cytoskeletal abundance of 12 proteins among 2813 detected proteins (adjusted $p$-value < 0.05 & $|\log_2$(fold change)| > 0.5)
Fig. 4. cytoPfkfb3 overexpression impacts mesoderm development in a glucose-concentration dependent manner. (A) Total number of somites in E10.5 embryos (mean ± s.d; unpaired Welch’s t-test; **p-value < 0.01). Ctrl, control embryos; Tg, cytoPfkfb3 embryos (crossed to Hprt-Cre line). (B,C) Number of formed somites and quantification of PSM explant length after 12-hour in vitro culture. (D) Whole mount mRNA in situ hybridization analysis for Lfng, Shh, and Uncx4.1 in PSM explants after 12-hour in vitro culture at varying glucose concentrations. Asterisks denote somites that formed during the in vitro culture. Scale bar, 100 µm. (E,F) Effect of mesoderm-specific overexpression of cytoPfkfb3 on PSM segmentation and elongation (12-hour incubation). The PSM explants were cultured in medium containing 10 mM glucose. Bar graphs show the number of newly formed somites during the culture (E), and the length of explants after the culture (F; mean ± s.d; unpaired Welch’s t-test; ***p-value < 0.001). (G) Real-time quantification of segmentation clock activity using Notch signaling activity reporter LuVeLu in PSM explants, shown as kymographs. Note that oscillatory reporter activity ceased in cytoPfkfb3/T-Cre samples during the experiment, while control samples showed ongoing periodic activity.

(Miyazawa et al. | Glycolytic flux-signaling in mouse embryos bioRxiv | 7)
Fig. 5. Effect of cytoPfkfb3 overexpression on Wnt and FGF target gene expression (A,B) Whole-mount mRNA in situ hybridization for Msgn (Wnt-target gene) and Dusp4 (FGF-target gene) in the PSM explants. Explants were cultured for 12 hours under various glucose conditions, as indicated. Shh and Uncx4.1 were used as a marker for neural tissue and posterior somite boundary, respectively. Expression domain of Msgn and Dusp4 is indicated by yellow rectangles. Note the glucose-dose dependent loss of Msgn expression in cytoPfkfb3 explants (Tg; crossed to Hprt-Cre line). In contrast, Dusp4 expression appeared unaffected in cytoPfkfb3 explants. Asterisks mark somites that formed during the culture. Scale bar, 100 µm.

Fig. 6. Subcellular localization of glycolytic enzymes are responsive to FBP treatment. (A) Effects of FBP treatment on subcellular localization of glycolytic enzymes. PSM explants were cultured for three hours in media containing 2.0 mM glucose and supplemented with 20 mM F6P or FBP. In addition to whole cell lysates (WCL), protein extracts were prepared from cytoplasmic (CYT), membrane (MEM), nuclear-soluble (NUC), chromatin-bound (CHR), and cytoskeletal (SKEL) fractions (n = 3 biological replicates). Abundance ratios (log₂[F6P/FBP-treated/control]) of glycolytic enzymes (in blue) were compared to those of non-glycolytic proteins (the rest, in gray) for statistical analysis (unpaired two-sample Wilcoxon test, *p-value < 0.05, ***p-value < 0.001, ****p-value < 0.0001, n.s., not significant). (B) Effects of FBP on the abundance of glycolytic enzymes in the nuclear soluble fraction. Subcellular protein fractionation was performed following one hour incubation of PSM explants in the media containing 0.5 mM glucose and supplemented with 20 mM FBP (n = 6 biological replicates; paired t-test, **p-value < 0.01, n.s., not significant).
Identifying FBP as a sentinel metabolite for glycolytic flux in developing mouse embryos.

In this work, we investigated how glycolytic flux impacts mouse embryo mesoderm development, seeking to decipher the underlying mechanisms. First, we aimed to identify sentinel metabolites whose concentrations mirror glycolytic flux in mouse embryos (10, 42–44). The identification of sentinel metabolites is critical, as steady state metabolite levels are generally poor indicators of metabolic pathway activities (45). By investigating how steady state metabolite levels respond to an alteration in glycolytic flux upon glucose titration, we identified aspartate, FBP, and lactate as potential sentinel glycolytic metabolites whose steady state levels were either positively (i.e. FBP and lactate) or negatively (i.e. aspartate) correlated with extracellular glucose levels (Figure 1B). Similar changes were observed upon glycolytic activation by cytoPfkfb3 overexpression (Figure 3C). Remarkably, we found that FBP levels exhibit a strong linear correlation with a wide range of glucose concentrations, showing a 45-fold increase from 0.5 mM to 10 mM glucose conditions (Figure 1A). Previous studies suggested that the reversible reactions between FBP and PEP allow coupling of FBP to lower glycolytic flux (43), and importantly that feedforward activation of pyruvate kinase by FBP enables the cell to establish a linear correlation between FBP and glycolytic flux over a wide range of FBP concentrations (43, 46). Such properties of lower glycolytic reactions may allow FBP to function as a generic sentinel metabolite for glycolytic flux in various biological contexts, from bacteria to mammalian cells (10, 33, 42, 43). This study extends such a finding of FBP as a glycolytic sentinel metabolite to in vivo mammalian embryos.

FBP as a flux signaling metabolite connecting glycolytic-flux and PSM development.

Interestingly, in addition to being a sentinel for glycolytic flux, FBP has been shown to carry signaling functions, hence relaying flux information to downstream effectors, such as transcription factors and signaling molecules (10, 42, 43). To test if such a flux-signaling function exists also in mouse embryos, we combined two complementary approaches, i.e. medium-supplementation of FBP (Figure 2) and, importantly, a genetic mouse model to increase glycolytic flux (Figure 3–5).

First, we revealed that high doses of FBP impaired mesoderm segmentation, disrupted the segmentation clock activity and led to downregulation of Wnt and Fgf target gene expression in the PSM (Figure 2).

Using 13C-tracing experiments, we showed that exogenous FBP could be taken up by PSM cells (Figure S3C), an important control considering the debate re-
through the cell membrane (47). Interestingly, the effect of FBP appear most pronounced in the posterior, most undifferentiated PSM cells, while segmentation clock activity per-
sists in the anterior PSM cells upon medium-supplementation of FBP (Figure 2A). This argues against a pleiotropic, toxic effect of FBP and suggests a more specific effect triggered by increased FBP levels. As a second, complementary approach to alter glycolytic flux and hence FBP levels, we aimed to increase glycolytic flux, and FBP levels, by acting on the ac-
tivity of Pfk, the rate limiting glycolytic enzyme, in a ge-
netic manner (Figure 3). To this end, we generated conditional transgenic mice which overexpress cytoPfkfb3 in a Cre-dependent manner. We showed that cytoPfkfb3 overex-
pression was indeed effective in increasing glycolytic flux in PSM explants, with a two-fold increase in secreted lactat-
tate (Figure 3B). Such a strong activation of glycolysis has been shown to be difficult to achieve by overexpression of isoforms, wild-type glycolytic proteins in mammalian cell lines (33, 35). Of note, GC-MS analysis showed that cytoPfkfb3 overexpression was effective in increasing intracellular FBP levels (Figure 3C). Because the extent of glycolytic activa-
tion by cytoPfkfb3 was dependent on glucose concentration in the culture media (Figure 3B), we can titrate the effects of cytoPfkfb3 overexpression by increasing glucose. There-
fore, the cytoPfkfb3 transgenic mouse line that we generated is a powerful, genetic mouse model to study the function of glycolysis and, more importantly, that of a sentinel glycolytic metabolite FBP, in various biological contexts.

Functionally, overexpression of cytoPfkfb3 led to impair-
ment of PSM segmentation at 10 mM or higher glucose concentrations, while wild-type PSM developed properly, at least qualitatively, at this glucose concentration (Figure 4, S1). The abnormal PSM development accompanied disrup-
tion of the segmentation clock activity and suppression of Wnt-target gene expression, while expression of FGF-target gene remained comparable to control. These phenotypes are reminiscent of our observation that intermediate levels (10 mM) of exogenous FBP suppressed mRNA expression of Msgn but not of Dusp4 (Figure 2B). This data hence indicate that cytoPfkfb3 overexpression phenocopies the effect of the FBP-supplementation on PSM development.

Combined, these findings provide evidence that the sentinel glycolytic metabolite FBP exerts a signaling function in PSM development.

The role of regulated flux at the level of PFK.

One key finding we made is that PSM development and segmentation clock dynamics are particularly sensitive to changes in FBP levels that result from bypassing or impairing flux-regulation by Pfk. Hence, we found that supplemen-
tation of FBP, but not its precursor metabolite F6P, which is converted to FBP by Pfk, impaired mesoderm development and arrested segmentation clock oscillations. Along similar lines, cytoPfkfb3 overexpression, which interferes with allo-
steric regulation of Pfk, very effectively impaired PSM de-
velopment and suppressed Wnt signaling target gene expres-
sion in a glucose-dose dependent manner. In contrast, the ac-
tivation of glycolysis with intact flux-regulation by Pfk, such as the glucose titration experiment in control embryos, had relatively minor functional consequences on gene expression (Figure S3), segmentation and clock oscillation (Figure S1), while FBP levels were significantly altered (Figure 1).

We conclude from these results that flux-regulation by Pfk carries a critical role and offer several, non-exclusive interpre-
tations. First, our findings might simply indicate that flux-
regulation by Pfk plays a critical role in keeping FBP steady state levels within a critical range. In addition, these results are also compatible with a view in which flux-regulation by Pfk provides a critical dynamical control over glycolytic flux and FBP levels. While speculative at this point, our findings hence bear resemblance to previous classical findings showing the role of Pfk as a key regulator of glycolytic oscillations (48–50). Glycolytic oscillations and a function of metabolic rhythms have not been identified in embryonic development. Nevertheless, our results are compatible with the hypothesis that the regulation of FBP dynamics by Pfk could play a role during PSM patterning and segmentation clock oscillations.

To probe for this possibility more directly, we are currently exploring strategies to investigate the presence of metabolic rhythms in embryonic cells using biosensors.

Wnt signaling as a link between glycolytic-flux and the segmentation clock.

We show that Wnt-target gene expression is responsive to glycolytic flux: while lowering glucose concentration corre-
lated with an upregulation of Wnt target genes, the opposite effect was found when glucose concentration was increased (Figure S2). Consistently, we found that Wnt target gene expression showed a decrease in conditions of FBP supplemen-
tation and cytoPfkfb3 overexpression (Figure 2B, 5A). Previously, it was shown that Wnt signaling can promote glycolysis directly or indirectly (16, 51). Therefore, our findings sug-
gest that in the PSM there is a negative-feedback regulation from glycolysis to Wnt signaling. Contrary to our findings, a previous study performed in cultured chick embryos has suggested that glycolysis regulates Wnt signaling positively, via the regulation of intracellular pH levels (30). While the reason for this discrepancy in how glycolysis impacts Wnt signaling is currently unknown, these combined findings do highlight that Wnt signaling is responsive to glycolytic-flux and hence a link between metabolism and PSM development.

Given the central function of Wnt signaling in development, stem cells and disease, a future key interest will be to reveal its link to metabolism and in particular glycolytic flux in these different contexts. In addition, as FBP can be considered as a universal sentinel for glycolytic-flux in living organisms, it will be crucial to reveal the mechanisms of how cells integrate steady state FBP levels in these different contexts.

Impact of altered glycolytic-flux and FBP levels on subcellular protein localization.

As one mechanism by which FBP levels are integrated into cellular programs, we propose that FBP levels impact subcell-
ular localization of proteins, some of which might function as FBP sensor molecules. Here, we revealed that several gly-
glycolytic enzymes including Aldoa and Pfkl are amongst those proteins altering their subcellular localization in response to FBP supplementation or cytoPfkfb3 overexpression (Figure 6, 7). Of note, we found that several glycolytic enzymes are, in the first place, localized in the nuclear soluble fraction (Figure S6C–E), raising the question about their functional role within the nuclear compartment. So far, glycolytic activity is thought to be restricted to the cytosol and hence nuclear localization of these enzymes raises the attractive hypothesis that their subcellular compartmentalization is linked to a non-metabolic, moonlighting function (52–56).

Additionally recent evidence in several biological systems highlights that subsets of metabolic reactions, for instance, from the mitochondrial TCA-cycle, take place also in the nucleus in order to maintain local supply of substrates for epigenetic modifications (57, 58). Thus, one possibility is that specific glycolytic reactions are taking place also in the nucleus, for instance to provide a local source of co-factors (e.g. NAD+) and/or substrates (e.g. acetyl-CoA, O-GlcNAc) for post-translational modifications of proteins. This emerging view of compartmentalized, local metabolic reactions as a way to regulate cellular functions has been recently supported by experimental evidence (41, 59–61).

While future studies will need to reveal if nuclear localization of glycolytic enzymes is linked to their moonlighting functions or metabolic compartmentalization, our finding that their subcellular localization is glycolytic flux-sensitive reveals a potentially general mechanism of how metabolic state is integrated into cellular programs. It is particularly interesting to find that Pfkl and Aldoa, enzymes that are known to directly bind to FBP, show a flux-sensitive subcellular localization (Figure 6, 7). This raises the possibility that FBP-protein interaction impacts, directly or indirectly, protein localization within a cell. Interestingly, a previous study has proposed that FBP is implicated in allosteric regulation of a multitude of proteins involved in either metabolic as well as non-metabolic processes in Escherichia coli (62). Therefore, revealing the FBP allosterome and investigating the impact of allosteric interactions on protein localization and, more generally, on protein function, is of central importance and a key future objective (63). Excitingly, emerging techniques are now becoming available that enable interrogation of metabolite-protein interaction (62, 64) and we are currently exploring the possibility to decipher allosteromes in complex biological samples, such as in mouse embryos.

Outlook.

Using mouse embryo mesoderm development as a model system, our study identifies FBP as a sentinel, flux-signaling metabolite connecting glycolysis and developmental signaling pathways. Considering that cellular metabolism responds to various environmental cues, this integration of the metabolic state into cellular programs signifies an attractive mechanistic link of how environmental cues impact phenotype (65, 66). Interestingly, the role of FBP as a flux-signaling metabolite has been demonstrated in bacteria (3) and hence predates the origin of signaling pathways involved in multicellular organism development, such as the Wnt signaling pathway, which appeared only from the metazoa (67). From this perspective, it is of great interest to ask how metabolic flux-signaling has been integrated into signaling pathways involved in multicellular organism development in the course of evolution. Future studies addressing this fundamental question will shed a new light on potential roles of metabolism as regulators/modulators of organismal phenotype.

Materials and Methods

Please refer to supplementary materials (Supplementary Note 1) for detailed materials and methods.

Acknowledgements

We thank Theodore Alexandrov for helpful discussion and Jonathan Rodenfels and Joel I Perez-Perri for critical comments on the manuscript. We thank Jason Chesney for kindly sharing the Flag-Pfkfb3(K472A/K473A) plasmid, Yvonne Petersen for performing blastocyst injection of ESCs, Jana Kress for generating anti-Pfkl antibody, the nCounter core facility at the university of Heidelberg for expression analysis using NanoString technology, Bernd Klaus for helping with statistical analysis of the NanoString data and all the member of the Aulehla group for their support and helpful discussion. This work was supported by the EMBL Advanced Light Microscopy Facility (ALMF) and the Laboratory Animal Resources (LAR).

Funding

The work was supported by: the European Molecular Biology Laboratory (K.P., M. B., A.A.); the EMBL International PhD Programme (M.T.S.; N.P.; E.K.); and the EMBL Interdisciplinary Postdoc (EI3POD) programme under H2020 Marie Sklodowska-Curie Actions COFUND (grant number 664726; H.M.; H.M.H.). H.M. was further supported by the Japan Society for the Promotion of Science (JSPS). H.M.H. was also supported by the Sigrid Juselius Foundation (Sigrid Juselius Stiftelse). This work further was supported by the German Research Foundation/DFG (project SFB 1324 – project number 331351713) to A.A.

Author contributions

H.M. designed the project, performed the experiments, analyzed the data, wrote and revised the original manuscript. M.T.S. designed the project, performed the experiments, analyzed the data, and revised the manuscript. N.P. performed the NanoString analysis, analyzed the data, and commented on the manuscript. E.K. performed the GC-MS analysis, analyzed the data, and commented on the manuscript. H.M.H. performed the subcellular proteome analysis, analyzed the data, and commented on the manuscript. N.T. performed gene targeting of ESCs for generation of Rosa26-stopfloxed-cytoPfkfb3 mice. K.R.P. supervised the GC-MS analysis. M.B. supervised the subcellular proteome analysis. A.A. conceptualized and supervised the project, and wrote the manuscript.

Competing financial interests

The authors declare that they have no conflict of interest.
References

A. C. Oates. Genetic oscillations: a doppler effect in embryonic pattern formation. Science, 345(6193):222-5, 2014. ISSN 1536-874X (Electronic) 0036-8075 (Linking). doi: 10.1126/science.1253089.

M. Matsuda, H. Hayashi, J. Garcia-Ojalvo, K. Yoshikawa-Kobayashi, R. Kageyama, Y. Yamada, C. Alex, M. Ikaya, J. Topouzis, K. Ogiwara, A. Ishikawa, and S. Divine. Coupling deoxyribonucleic acid oscillation to gene expression in primary murine embryonic stem cells. Cell, 134(6):925-38, 2008. ISSN 0092-8674 (Print) 1097-4674 (Online). doi: 10.1016/j.cell.2008.08.032.

K. Yoshikawa-Kobayashi, M. Matsumiya, Y. Niino, A. Isomura, H. Kageyama, and M. Miyawaki. A mathematical model of gene regulatory networks in the segmentation clock. Med Biol Eng Comput, 48:583–611, 2014. ISSN 1545-2948 (Print) 1545-2956 (Online). doi: 10.1007/s11517-014-1093-0.

M. Ogunrma, Y. Harima, A. Tarazona, M. Diaz-Cuadros, A. Michaut, T. Ishitani, F. Xiong, A. Gossler, and B. G. Herrmann. Expression of msgn1 in the presomitic mesoderm is controlled by synergism of wnt signaling and b6. Cell Rep, 8(4):784–9, 2007. ISSN 2219-221X (Print) 2219-221X (Online). doi: 10.1016/j.celrep.2007.01.007.

J. M. Asara, L. C. Cantley, and G. M. Wulf. Phosphoinositide 3-kinase regulates glycolysis via activation of protein kinase b. Trends Biochem Sci, 31(10):494–501, 2006. ISSN 1557-7988 (Print) 0091-7451 (Online). doi: 10.1016/j.tibs.2006.08.004.

C. H. Chang, J. D. Curtis, Jr. Maggi, L. B., B. Faubert, A. V. Villarino, D. O'Sullivan, S. C. A. C. A., and J. M. Thevelein. Fructose-1,6-bisphosphate couples glycolytic flux to activation of ras. J Biol Chem, 278(1):64–70, 2003. ISSN 0021-9258 (Print) 1021-2269 (Online). doi: 10.1074/jbc.M207671200.

K. F. Sonnen, V. M. Lauschke, J. Uraji, H. J. Falk, Y. Petersen, M. C. Funk, M. Beaucage, P. Francois, C. A. Merten, and A. Aulehla. Modulation of phase shift between wnt and notch signaling oscillations during somitogenesis. Cell, 172(5):1090–1092, 2018. ISSN 1077-4674 (Print) 1077-4687 (Online). doi: 10.1016/j.cell.2018.04.004.

M. Ogunrma, Y. Harima, A. Tarazona, M. Diaz-Cuadros, A. Michaut, T. Ishitani, F. Xiong, and O. Pourquié. Intracellular pH controls downstream of glycolysis in amniotic embries. Nature, 584(7819):98–101, 2020. ISSN 1476-4687 (Print) 1476-4674 (Online). doi: 10.1038/s41586-020-02985-0.

12 | bioRxiv

Miyawaza et al. | Glycolytic flux-signaling in mammalian embryos

bioRxiv preprint [https://doi.org/10.1101/2021.12.20.473441]; this version posted December 23, 2021. The copyright holder for this preprint (which was not peer reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It may be available under a CC-BY 4.0 International license.
Glycolytic flux-signaling in mouse embryos
Supplementary Note 1: Materials and Methods

Ex vivo culture of PSM explants.

All animals were housed in the EMBL animal facility under veterinarians’ supervision and were treated following the guidelines of the European Commission, revised directive 2010/63/EU and AVMA guidelines 2007. The detection of a vaginal plug was designated as embryonic day (E) 0.5, and all experiments were conducted with E10.5 embryos. PSM explants with three intact somites were collected using microscalps (Feather Safety Razor, No. 715, 02.003.00.715) in DMEM/F12 (without glucose, pyruvate, glutamine, and phenol red; Cell Culture Technologies) supplemented with 0.5–25 mM glucose (Sigma-Aldrich, G8769), 2.0 mM glutamine (Sigma-Aldrich, G7513), 1.0% (w/v) BSA (Cohn fraction V; Equitech-Bio, BAC62), and 10 mM HEPES (Gibco, 15360-106). The explants were then washed with pre-equilibrated culture medium (DMEM/F12 supplemented with 0.5–25 mM glucose, 2.0 mM glutamine, and 1.0% (w/v) BSA) and were transferred to 8-well chamber slides (Lab-Tek, 155411) filled with 160 µl of the pre-equilibrated culture medium. When assessing the impacts of glycolytic intermediates on PSM development, culture medium supplemented with a glycolytic intermediate (i.e. fructose 1-phosphate (Sigma-Aldrich, F1127), fructose 6-phosphate (Sigma-Aldrich, F3637), fructose 1,6-bisphosphate (Santa Cruz, sc-221476), 13C6-fructose 1,6-bisphosphate (Cambridge Isotope laboratories, CLM-8962), 3-phosphoglycerate (Sigma-Aldrich, P8877)) was prepared with pre-equilibrated culture medium right before dissection. Following ex vivo culture under 5% CO2, 60% O2 condition, the explants were washed with PBS and were fixed overnight with 4% (v/v) formaldehyde solution (Merck, 1040031000) at 4°C for further analyses.

Generation of Rosa26-stop<sup>flxed</sup>-cytoPfkfb3 mouse line.

Flag-Pfkfb3(K472A/K473A) (hereafter termed as cytoPfkfb3) from (35) was amplified by PCR using the following primers: forward 5’-TAGGCCCCGCCCACCATGACTCAAGGACGCAGACG-3’ and reverse 5’-TGCGCCGCGCGAAATGGAATGAAACCAGACAC-3’. The resulting amplicon was then cloned into the Rosa26 targeting vector Ai9 (68) using FseI restriction enzyme to generate the loxP-stop-loxP-Flag-cytoPfkfb3 construct. Conditional cytoPfkfb3 transgenic mouse line was generated by standard gene targeting techniques using RI embryonic stem cells. Briefly, chimeric mice were obtained by C57BL/6 blastocyst injection and then outbred to establish the line through germline transmission. Rosa26-stop<sup>flxed</sup>-cytoPfkfb3 mouse line was maintained by crossing to CD1 mouse strain.

Genotyping.

The following mice used in this study were described previously and were genotyped using primers described in these references: T-Cre (36), Hprt-Cre (69), LuVeLu (23). The primers used for genotyping of Rosa26-stop<sup>flxed</sup>-cytoPfkfb3 mice were as follows: forward 5’-GAGCTGCAGTGGAGTAGGCG-3' and reverse 5’-CTCGACCATGGTAATAGCGA-3' (predicted product size, 580 bp). The primers used for genotyping of Rosa26-cytoPfkfb3 mice were as follows: forward 5’-GGCTTCTGGCGTGTGACCGG-3' and reverse 5’-GGCTTCTGGCGTGTGACCGG-3' (predicted product size, 580 bp). For polymerase chain reaction (PCR), OneTaq 2X Master Mix with Standard Buffer was utilized (New England Biolabs).

Time-lapse imaging of LuVeLu embryos.

Imaging was performed as described before (70). In brief, samples were excited by 514 nm-wavelength argon laser or 960 nm-wavelength Ti:Sapphire laser (Chameleon-Ultra, Coherent) through 20× Plan-Apochromat objective (numerical aperture 0.8). In some experiments, samples were placed into agar wells (3% low Tm agarose, Biozyme, 840101) with 600 nm-width to restrain tissue movements during imaging. Image processing was done using the Fiji software (71).

In situ hybridization.

Fixed PSM explants were dehydrated with methanol and were stored at -20°C until use. Whole mount in situ hybridization was performed as described in (23).

Gas chromatography-mass spectrometry (GC-MS) analysis.

Wild-type and cytoPfkfb3 transgenic PSM explants with no somite were cultured ex vivo for three hours under different glucose conditions, as described above. After washing twice with ice-cold PBS, the explants were snap frozen by liquid N2, and were stored at -80°C until use. Metabolites were extracted from the 25x explants by mechanically dissociating tissues by pipetting in 100 µl ice-cold methanol supplemented with ribitol (5.0 µg/mL) as an internal standard. For metabolite extraction from the conditioned medium, 20 µl of the medium was mixed with 40 µl of ice-cold methanol supplemented with ribitol. After incubation at 72°C for 15 min, one volume of ice-cold MilliQ water was added, followed by centrifugation at 14,000 rpm at 4°C for 10 mins. The supernatants were transferred to amber glass vials (Agilent, 5183-3410) and were dried by centrifugal evaporator EZ-2 Plus (SP Scientific) (30°C, medium boiling point). The dried metabolite extracts were reconstituted with 40 µL of 20 mg/mL methoxyamine hydrochloride (Alfa Aesar, 593-56-6) solution in pyridine (Sigma-Aldrich, 437611) for 90 min at 37°C, followed by addition of 80 µL N-methyl-trimethylsilyl-trifluoroacetamide (MSTFA) (Alfa Aesar, 24589-78-4) and 10-hour incubation at room temperature (72, 73). GC-MS analysis was performed using a Shimadzu TQ8040 GC-triple quadrupole) MS system (Shimadzu Corp.) equipped with a 30m x 0.25 mm x 0.25 µm ZB-50 capillary column (7HG-G004-11; Phenomenex). One µL of the sample was injected in split mode (split ratio = 1:5) at 250°C using helium as a carrier gas with a flow rate of 1 mL/min. GC oven temperature was held at 100°C for 4 min followed by an increase to 320°C with a rate of 10 °C/min, and a final constant temperature period at 320°C for 11 min. The interface and the ion source were held at 280°C and 230°C, respectively. The detector was operated both in scanning mode (recording in the range of 50-600 m/z) as well as in MR mode (for specified metabolites). For peak annotation, the GCMSsolution software (Shimadzu Corp.) was utilized. The metabolite identification was based on an in-house database with analytical standards utilized to define the retention time, the mass spectrum and marker ion fragments for all the quantified metabolites. The metabolite quantification was carried out by integrating the area under the curve of the MRM transition of each metabolite. The data were further normalized to the area under the curve of the MRM transition of ribitol.
**Liquid chromatography-mass spectrometry (LC-MS) analysis.**

After three-hour culture in the presence of 20 mM $^{13}$C$_6$-FBP, PSM explants were washed with cold 154 mM ammonium acetate, snap frozen in liquid N$_2$ and then dissociated in 0.5 mL ice-cold methanol/water (80:20, v/v) containing 0.20 µM of the internal standard lamivudine (Sigma-Aldrich, P8241H). The resulting suspension was transferred to a reaction tube, mixed vigorously and centrifuged for 2 min at 16,000 x g. Supernatants were transferred to a Strata® C18-E column (Phenomenex, 8B-S001-DAK) which were previously activated with 1 mL of CH$_3$CN and equilibrated with 1 mL of MeOH/H$_2$O (80:20, v/v). The eluate was dried in a vacuum concentrator. The dried metabolite extracts were dissolved in 50 µL of 5 mM NH$_4$OAc in CH$_3$CN/H$_2$O (75.25, v/v), and 3 µL of each sample was applied to an amide-HILIC (2.6 µm, 2.1 x 100 mm, Thermo Fisher, 16726-012105). Metabolites were separated at 30°C by LC using a DIONEX Ultimate 3000 UPLC system and the following solvents: solvent A consisting of 5 mM NH$_4$OAc in CH$_3$CN/H$_2$O (5:95, v/v) and solvent B consisting of 5 mM NH$_4$OAc in CH$_3$CN/H$_2$O (95:5, v/v). The LC gradient program was: 98% solvent B for 1 min, followed by a linear decrease to 40% solvent B within 5 min, then maintaining 40% solvent B for 13 min, then returning to 98% solvent B in 1 min and then maintaining 98% solvent B for 5 min for column equilibration before each injection. The flow rate was maintained at 350 µL/min. The eluent was directed to the hESI source of the Q Exactive mass spectrometer (QE-MS; Thermo Fisher Scientific) from 1.85 min to 18.0 min after sample injection. The scan range was set to 69.0 to 550 m/z with a resolution of 70,000 and polarity switching (negative and positive ionisation). Peaks corresponding to the calculated metabolites masses taken from an in-house metabolite library (MIM +/− H$^+$ ± 2 mmU) were integrated using the El-MAVEN software (74).

**Extracellular lactate measurement.**

Condition medium was collected following 12-hour *ex vivo* culture of PSM explants, and was stored at -80°C until use. Fluorometric lactate measurements were performed with the Lactate Assay Kit (Biovision, K607) following manufacturer’s instructions with a slight modification. The reaction volume was reduced to 50 µL, and 0.5–1.0 µL of the conditioned medium was used for the analysis.

**Whole embryo roller-culture and TUNEL staining.**

Embryos were collected with the intact yolk sac at E8.5 in DMEM (1.0 g/L glucose, without glutamine and phenol red) (Gibco, 11880-028) supplemented with 2.0 mM glutamine, 10% FCS, and 1% (v/v) penicillin/streptomycin (Gibco, 15140-122). The embryos were cultured for 24 hours using the roller bottle culture system in 50% rat serum/DMEM (supplemented with 2.0 mM glutamine, 10% FCS, and 1% (v/v) penicillin/streptomycin) under 8% CO$_2$ for 24 hours. Embryos were collected with the intact yolk sac at E8.5 in DMEM (1.0 g/L glucose, without glutamine and phenol red) (Gibco, 11880-028) supplemented with 2.0 mM glutamine, 10% FCS, and 1% (v/v) penicillin/streptomycin (Gibco, 15140-122). The embryos were cultured for 24 hours using the roller bottle culture system in 50% rat serum/DMEM (supplemented with 2.0 mM glutamine, 10% FCS, and 1% (v/v) penicillin/streptomycin) under 8% CO$_2$. Embryos were cultured for 24 hours using the roller bottle culture system in 50% rat serum/DMEM (supplemented with 2.0 mM glutamine, 10% FCS, and 1% (v/v) penicillin/streptomycin) under 8% CO$_2$, 20% O$_2$, and 72% N$_2$ (flow rate, 20 mL/min) condition (38). Following the whole embryo culture, the embryos without the yolk sac and amniotic membrane were fixed with 4% formaldehyde overnight at 4°C. TUNEL staining was done with In Situ Cell Death Detection Kit (Roche, 12156792910) following manufacturer's instructions, followed by DAPI (0.5 µg/mL) staining.

**Subcellular proteome analysis by mass spectrometry.**

Effect of FBP and F6P on subcellular localization. Treated mouse PSMs were washed twice with ice-cold PBS and subjected to subcellular protein extraction using a Subcellular Protein Fractionation for Cultured Cells kit (Thermo Fisher Scientific, #78840). 8–11x PSMs were used for each condition in each replicate. PSMs were dissociated in 10 µL of CEB buffer per PSM by pipetting, after which 10 µL (i.e. 1x PSM worth) of uncleared lysate was taken as the whole-cell lysate (WCL) sample. The rest of the extraction was carried out following manufacturer’s instructions using buffer amounts scaled according to the number of PSMs in the sample. The resulting fractions were stored at -80°C before further processing. Subsequently, CYT and MEM fractions were reduced in volume to ~50 µL in a speedvac, and each subcellular protein fraction was denatured with 1% SDS at 95°C for 5 minutes, after which residual nucleic acids were degraded with benzoxane (EMD Millipore, #71206-25KUN; final concentration 0.1-1 U/µL) for 45 minutes at 37°C and 300 rpm until samples were no longer viscous.

Subcellular proteomics of cytoPfkfb3 transgenic embryos. Transgenic (Tg) and control (Cnt) PSM explants were subjected to subcellular protein extraction as above with the following exceptions: After extraction of the MEM fraction, protein from the remaining pellet (constituting the nuclear and cytoskeletal fractions) was extracted with the NEB buffer (with micrococcal nuclease) plus 1x SDS lysis buffer [50 mM HEPES-NaOH (pH 8.5), 1% SDS, 1 x Complete protease inhibitor cocktail (Roche, 1187358001)] and used directly for benzoxane treatment as above.

Sample preparation and LC-MS/MS. All samples were prepared for MS using a modified SP3 protocol (75). Briefly, protein samples were precipitated onto Sera-Mag SpeedBeads (GE Healthcare, #45152105050250 and #65152105050250) in the presence of 50% ethanol and 2.5% formic acid (FA) for 15 min at room temperature, followed by four washes with 70% ethanol on magnets. Proteins were digested on beads with trypsin and Lys-C (5 ng/µL final concentration each) in 90 mM HEPES (pH 8.5), 1% SDS, 1x cOmplete protease inhibitor cocktail (Roche, 1187358001) and used directly for benzonase treatment (Miyazawa et al., 2002). Samples were reconstituted in 10 µL water and labelled by adding 4 µL TMT label (20 µg/µL in acetonitrile (ACN)) (TMT10plex, Thermo Fisher Scientific) overnight at room temperature shaking at 500 rpm until samples were no longer viscous. All samples were prepared for MS using a modified SP3 protocol (75). Briefly, protein samples were precipitated onto Sera-Mag SpeedBeads (GE Healthcare, #45152105050250 and #65152105050250) in the presence of 50% ethanol and 2.5% formic acid (FA) for 15 min at room temperature, followed by four washes with 70% ethanol on magnets. Proteins were digested on beads with trypsin and Lys-C (5 ng/µL final concentration each) in 90 mM HEPES (pH 8.5), 1% SDS, 1x complete protease inhibitor cocktail (Roche, 1187358001) and used directly for benzonase treatment as above.

Sample preparation and LC-MS/MS. All samples were prepared for MS using a modified SP3 protocol (75). Briefly, protein samples were precipitated onto Sera-Mag SpeedBeads (GE Healthcare, #45152105050250 and #65152105050250) in the presence of 50% ethanol and 2.5% formic acid (FA) for 15 min at room temperature, followed by four washes with 70% ethanol on magnets. Proteins were digested on beads with trypsin and Lys-C (5 ng/µL final concentration each) in 90 mM HEPES (pH 8.5), 1% SDS, 1x complete protease inhibitor cocktail (Roche, 1187358001) and used directly for benzonase treatment as above.

**Sample preparation and LC-MS/MS.**

All samples were prepared for MS using a modified SP3 protocol (75). Briefly, protein samples were precipitated onto Sera-Mag SpeedBeads (GE Healthcare, #45152105050250 and #65152105050250) in the presence of 50% ethanol and 2.5% formic acid (FA) for 15 min at room temperature, followed by four washes with 70% ethanol on magnets. Proteins were digested on beads with trypsin and Lys-C (5 ng/µL final concentration each) in 90 mM HEPES (pH 8.5), 1% SDS, 1x complete protease inhibitor cocktail (Roche, 1187358001) and used directly for benzonase treatment as above.

**Sample preparation and LC-MS/MS.**

All samples were prepared for MS using a modified SP3 protocol (75). Briefly, protein samples were precipitated onto Sera-Mag SpeedBeads (GE Healthcare, #45152105050250 and #65152105050250) in the presence of 50% ethanol and 2.5% formic acid (FA) for 15 min at room temperature, followed by four washes with 70% ethanol on magnets. Proteins were digested on beads with trypsin and Lys-C (5 ng/µL final concentration each) in 90 mM HEPES (pH 8.5), 1% SDS, 1x complete protease inhibitor cocktail (Roche, 1187358001) and used directly for benzonase treatment as above.
to untreated) or 12 (comparison of Tg to Ctrl) fractions on an Ultimate 3000 (Dionex) HPLC using high-pH reversed-phase chromatography (running buffer A: 20 mM ammonium formate pH 10; elution buffer B: ACN) on an X-bridge column (2.1 x 10 mm, C18, 3.5 µm, Waters). Prefractionated peptides were vacuum dried.

For LC-MS/MS analysis, peptides were reconstituted in 0.1% FA, 4% ACN and analyzed by nanoLC-MS/MS on an Ultimate 3000 RSLC (Thermo Fisher Scientific) acquired to a Fusion Lumos Tribrid (Thermo Fisher Scientific) mass spectrometer, using an Acclaim C18 PepMap 100 trapping cartridge (5 µm, 300 µm i.d. x 5 mm, 100 Å) (Thermo Fisher Scientific) and a nanoEase M/Z HSS C18 T3 (100Å, 1.8 µm, 75 µm x 250 mm) analytical column (Waters). Solvent A: aqueous 0.1% FA; Solvent B: 0.1% FA in ACN (all LC-MS grade solvents are from Thermo Fisher Scientific). Peptides were loaded on the trapping cartridge using solvent A for 3 min with a flow of 30 µl/min. Peptides were separated on the analytical column with a constant flow of 0.3 µl/min applying a 120 min gradient of 2–40% of solvent B in solvent A. Peptides were directly analyzed in positive ion mode with a spray voltage of 2.2 kV and a ion transfer tube temperature of 275 °C. Full scan MS spectra with a mass range of 375–1500 m/z were acquired on the orbitrap using a resolution of 120,000 with a maximum injection time of 50 ms. Data-dependent acquisition was performed with a maximum cycle time of 3 s. Precursors were isolated on the quadrupole with an intensity threshold of 2e5, charge state filter of 2–7, isolation window of 0.7 m/z. Precursors were fragmented using HCD at 38% collision energy, and MS/MS spectra were acquired on the orbitrap with a resolution of 30,000, maximum injection time of 54 ms, normalized AGC target of 200%, with a dynamic exclusion window of 60 s.

Data analysis. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (76) partner repository with the dataset identifier PXD029988. Mass spectrometry raw files were processed using IsobarQuant (77) and peptide and protein identification was obtained with Mascot 2.5.1 (Matrix Science) using a reference mouse proteome (uniprot Proteome ID: UP000000589, downloaded 14.5.2016) modified to include known common contaminants and reversed protein sequences. Mascot search parameters were: trypsin; max. 2 missed cleavages; peptide tolerance 10 ppm; MS/MS tolerance 0.02 Da; fixed modifications: Carbamidomethyl (C), TMT10plex (K); variable modifications: Acetyl (Protein N-term), Oxidation (M), TMT10plex (N-term).

IsobarQuant output data was analyzed on a protein level in R using in-house data analysis pipelines. In brief, protein data was filtered to remove contaminants, proteins with less than 2 unique quantified peptide matches as well as proteins, which were only detected in a single replicate. Subsequently, protein reporter signal sums were normalized within each TMT set using the vsn package (78). Significantly changing proteins between the treated and untreated sample were identified by applying a limma analysis (79) on the vsn-corrected values. Replicates were treated as covariates in the limma analysis for the comparison of FBP to F6P, as biological replicates were run as separate TMT sets. Multiple-testing adjustment of $p$ values was done using the Benjamini-Hochberg method.

Western blot analysis.

Primaries antibodies used in the study are as follows: anti-Aldolase A (Proteintech, 11217-1-AP, 1:5,000), anti-Tpi (Acris, AP16324PU-N, 1:5,000), anti-Gapdh (Millipore, MAB374, 1:5,000), anti-Pkm1/2 (Cell signaling, 3190, 1:5000), anti-Histone H2B (Millipore, 07-371, 1:10,000), anti-beta-Tubulin (Millipore, 05-661, 1:10,000), anti-Hsp90 (Cell signaling, 4874, 1:1,000). Mouse monoclonal antibody against Pfkl was generated by EMBL Monoclonal Antibody Core Facility using full-length Pfkl as an antigen. For protein expression and purification, full-length Pfkl transcript was amplified by reverse transcription (RT)–PCR using mouse embryo total RNA as a template and cloned into PET28M-SUMO3 vector (EMBL Protein Expression and Purification Core Facility) using AgeI and NotI restriction enzymes. Following primers were used for RT-PCR: forward 5’-TCATCTACCGGTGGAATGGCTACCGTGGACCTGGAGA-3’ and reverse 5’-TCATCTGGCGCCGTCGAGAACCCTTGTTATGCTAGGT-3’.

Gene expression analysis by NanoString nCounter Analysis System.

A custom probe set was designed to include 237 genes involved in glucose metabolism, Notch-, Wnt-, and FGF-signaling pathways. In addition, six positive controls, eight negative controls and housekeeping genes for normalisation (housekeeping genes used: Cltc, Gush, Hprt1 and Tubb5) were included in the probe set. Following three-hour culture with the specified glucose concentration, the PSM explants were further dissected immediately posterior to the neural tube to isolate the posterior PSM. Five posterior PSM samples were pooled per replicate and snap frozen by liquid N2. Total RNA was isolated using TRIzol reagent (Invitrogen) according to manufacturer’s instructions and concentrated using RNA Clean & Concentrator-5 Kit (Zymo research). RNA was hybridized to the probes at 65 °C, samples were inserted into the nCounter Prep Station for 3 hours, the sample cartridge was transferred to the nCounter Digital Analyzer, and counts were determined for each target molecule. Counts were analysed using nSolver Analysis Software Version 4.0, and sequentially subjected to background correction, positive control (quality control) and normalisation to housekeeping genes.

Statistical analysis.

Statistical analysis was performed with GraphPad PRISM 9 software. For the metabolome data, statistical analysis was performed with the Statistical Analysis for Microarray (SAM) package (80) using R. For Pearson correlation analysis, numpy (81), pandas (82), and scipy (83) libraries were used. For data visualization, matplotlib (84) library was utilized.
Fig. S1. PSM patterning is tolerated within a wide range of glucose concentrations. Whole mount in situ hybridization analysis for Lfng, Shh, and Uncx4.1 gene expressions in the PSM. PSM explants were incubated for 13 hours ex vivo in different glucose conditions. Kymographs show ongoing oscillatory dynamics of the Notch signaling activity reporter LuVeLu in the PSM in all conditions but 0.03 mM glucose condition. Scale bar, 100 µm.
Fig. S2. Effects of medium-supplementation of glycolytic intermediates on mesoderm elongation and segmentation. (A) Elongation of PSM explants during ex vivo culture. The explants were cultured in the medium containing 0.5 mM glucose and supplemented with 20 mM of F6P/FBP/3PG. The length of explants at three hour-incubation was used as the reference. (B) The number of newly formed somites during 12-hour ex vivo incubation. (C) $^{13}$C-tracing experiments with fully $^{13}$C-labelled FBP ($^{13}$C$_6$-FBP). The PSM explants were cultured for three hours in the medium containing 2.0 mM of glucose and supplemented with 20 mM $^{13}$C$_6$-FBP. (D) Kymographs showing dynamics of the Notch signaling activity reporter LuVeLu in the PSM. Explants were cultured in medium containing 0.5 mM glucose and supplemented with 20 mM fructose 1-phosphate (F1P).
Fig. S3. Modulation of Wnt-target gene expression upon glucose titration within PSM cells. Hierarchical clustering heatmap of genes whose expression levels showed linear correlation with extracellular glucose concentrations (linear regression analysis; adjusted p-value < 0.1). Following three-hour culture at varying concentrations of glucose, expressions of 237 genes were analyzed in the posterior PSM using the NanoString nCounter Analysis System. These genes included ones involved in glucose metabolism, Notch-, Wnt-, and FGF-signaling pathways. Fold changes were calculated using 5.0 mM glucose condition as the reference. Hierarchical clustering was performed using Ward's method with Euclidean distance.
Fig. S4. Steady state measurements of metabolites within cytoPfkfb3 and control PSM explants by GC-MS. Hierarchical clustering heatmap of metabolites detected in PSM explants. Metabolomics analysis was performed following three-hour culture of PSM explants at 10 mM glucose concentration (n = 4 biological replicates for each condition). Hierarchical clustering was performed using Ward’s method with Euclidean distance. Ctrl, control explants; Tg, cytoPfkfb3 explants (crossed to Hprt-Cre line).
Fig. S5. *cytoPfkfb3* transgenic embryos show defects in neural tube closure under normoglycemic conditions. (A) E8.5 embryos with the intact yolk sac were cultured for 24 hours at normoglycemic conditions using the whole embryo roller-culture (WEC) system. (B) Total number of somites after 24-hour of WEC. Data are represented as mean ± s.d. Ctrl, control embryos; Tg, *cytoPfkfb3* embryos (crossed to *Hprt-Cre* line); Tg_NTDs, *cytoPfkfb3* embryos with neural tube closure defects. (C) DAPI and TUNEL staining of the embryos following WEC. Midbrain region of the embryos is shown. Scale bar, 100 µm (ss, somite stage).
Fig. S6. Proteome analysis of subcellular protein localization in the PSM. (A, B) Volcano plots showing effects of FBP- or F6P-treatment on abundance of proteins in nuclear-soluble (A) or cytoskeletal fractions (B). Subcellular protein fractionation was performed following three-hour culture of PSM explants in the medium containing 2.0 mM glucose and supplemented with 20 mM FBP or F6P. Glycolytic proteins are highlighted in blue. (C) Density plot showing the number of proteins that are annotated to nuclear (shown in blue) or cytoplasmic (shown in orange) compartments (based on GO term). PSM explants cultured in the control medium containing 2.0 mM glucose were used for the analysis. All the detected-proteins are shown in gray. Glycolytic proteins are highlighted by blue lines, and marker proteins for the nuclear-soluble (i.e. Top2b) and cytoplasmic (i.e. Hsp90ab1) fractions are highlighted by black lines. (D) Abundance ratio of glycolytic proteins (marked by blue) between nuclear-soluble (NUC) and cytoplasmic (CYT) fractions. (E) Western blot analysis of glycolytic proteins following subcellular protein fractionation of the PSM explants cultured in the control medium containing 0.5 mM glucose.